Newsletter / White Papers

DelveInsight Newsletter / White Papers
Cancer in The United States (Vol. 1, Issue 2)

Cancer in The United States (Vol. 1, Issue 2)

US Cancer Statistics show that more than half a million suffer from this disease, which is the second leading cause of death in the country. The newsletter Cancer in the US substantiates the increasing incidence and prevalence of major cancer sub-types in the American patient population, drawing conclusions related to the seriousness of the matter. This edition further points out to the top selling cancer drugs in the country and how new and innovative therapies are being researched to limit the devastating impact of this debilitating disease. Read on to know more

Cancer Globally (Vol. 1, Issue 1)

Cancer Globally (Vol. 1, Issue 1)

Cancer has gripped the human society in its clutches in such a way that there has been many advancements to treat the same, but with little success. The full extent of the disease can only be measured by the population that it has plagued, and how varied it has become over the course of years. Cancer by Numbers provide us with the degree of devastation it has incurred among various populations, and provides us with a better idea on the level of progress needed to eradicate this morbid indication. It also sheds light on the blockbuster drugs along with potential therapies for the cancer.

Impact of BREXIT on Pharma Space

Impact of BREXIT on Pharma Space

BREXIT, the 'EXIT' of 'BRITAIN' from 'EUROPEAN UNION', shook the whole world when the United Kingdom voted in the favor of leaving the EU. This was mainly done to access greater control of the country's borders as well as economy, which also led to major impact on various countries that have conducted business and trade within the UK borders. After the vote, the country has been wrought in uncertainty related to political, regulatory and economic scenario.

Contact Us

India:+91-11-45689769, +91-9650213330
Outside India: +1(919)321-6187


New Delhi-110075, India

Latest Tweets

  • Copyright © 2017 Delveinsight.
  • Sitemap